Capri Holdings CPRI 深 滬
等待開盤 09-08 09:30:00 美东时间
13.56
+0.320
+2.42%
華盛通- 最 高13.75
- 今 開13.18
- 成交量 447.96万股
- 最 低 13.04
- 昨 收 13.24
- 總市值 15.41亿
- 52周最高 28.265
- 市盈率 靜 17.67
- 換手率 3.94%
- 52周最低 12.565
- 委 比 -2.63%
- 總股本 1.14亿
- 歷史最高 72.37
- 量 比 1.05
- 振 幅 5.36%
- 歷史最低 5.42
- 每 手 1
- 風險率 3.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多The Trade Desk to leave S&P 500 as Bloom Energy, Everpure, Illumina join index
S&P Dow Jones Indices on Friday said it will add Bloom Energy (BE), Everpure (P) and Illumina (ILMN) to the S&P 500 as part of a broad quarterly rebalancing scheduled to take effect before trading ope...
09-06 21:15
Catalyst watch: Apple's high-stakes iPhone event, Oracle, CPI, and the NFL returns
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Monday - September...
09-05 03:00
CareEdge assigns BB-/Positive rating to Capri Global’s US$300 million notes
Capri Global Capital Limited ( ($IN:CGCL) ) has shared an announcement. Capri G...
09-02 01:14
Capricor wins another upgrade on Deramiocel review extension
Shares of Capricor Therapeutics (CAPR) gained on Tuesday as Piper Sandler became the latest brokerage to upgrade the biopharma after the FDA’s recent decision to extend the review period for its lead ...
09-01 22:43
Capri Global Publishes Investor Presentation for September 2026 Roadshow
The latest announcement is out from Capri Global Capital Limited ( ($IN:CGCL) )...
09-01 11:53
Capricorn Metals completes sale of Big Springs project to Sentinel
An update from Capricorn Metals Ltd ( ($AU:CMM) ) is now available. Capricorn M...
08-26 11:07
Capricor upgraded at Oppenheimer as Deramiocel review extended
Following an over 8% jump in the previous session, shares of Capricor Therapeutics (CAPR) continued to rise in premarket trading on Tuesday as Oppenheimer upgraded the biotech after the FDA extended t...
08-25 20:26
Capricor rises as FDA extends Deramiocel action date
Capricor Therapeutics (CAPR) is up ~7% in Monday morning trading after announcing that the FDA has extended the action date for its BLA on Duchenne muscular dystrophy therapy Deramiocel by three month...
08-24 22:27
Capricor Therapeutics Faces FDA Delay for Deramiocel Review
Capricor Therapeutics ( ($CAPR) ) has provided an announcement. On August 24, 2...
08-24 21:58
Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA
The U.S. FDA has extended the PDUFA target action date for Capricor Therapeutics' BLA for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD), from August 22, 2026, to November 22, 2026. The extension follows the submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication focused on upper limb function. The FDA accepted the amendment, citing the significant unmet medical need in...
08-24 13:25
